Patents Assigned to ALLCRON PHARMA INC.
  • Kinase inhibitors exhibiting anti-cancer activity and their method of use
    Patent number: 12157742
    Abstract: Pharmaceutical compositions of the invention comprise kinase inhibitors having a disease-modifying action in the treatment of diseases associated with BCR-ABL activity that include cancer, including chronic myeloid leukemia, acute lymphoblastic leukemia, acute myeloid leukemia, chronic lymphocytic leukemia, multiple myeloma, lymphomas, and metastatic carcinoma.
    Type: Grant
    Filed: May 31, 2023
    Date of Patent: December 3, 2024
    Assignee: Allcron Pharma Inc.
    Inventors: Ayyappan Rajasekaran, Jon Swanson, Peter Kane, Julia Foster
  • Kinase inhibitors exhibiting anti-cancer activity and their method of use
    Patent number: 11697654
    Abstract: Pharmaceutical compositions of the invention comprise kinase inhibitors having a disease-modifying action in the treatment of diseases associated with BCR-ABL activity that include cancer, including chronic myeloid leukemia, acute lymphoblastic leukemia, acute myeloid leukemia, chronic lymphocytic leukemia, multiple myeloma, lymphomas, and metastatic carcinoma.
    Type: Grant
    Filed: March 18, 2019
    Date of Patent: July 11, 2023
    Assignee: ALLCRON PHARMA INC.
    Inventors: Ayyappan Rajasekaran, Jon Swanson, Peter Kane, Julia Foster